0 CHECKOUT

Boehringer Ingelheim GmbH - Product Pipeline Review - 2015

  • ID: 3387856
  • July 2015
  • 179 pages
  • Global Markets Direct
1 of 3

Boehringer Ingelheim GmbH - Product Pipeline Review - 2015

Summary

The report ‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2015’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boehringer Ingelheim GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables
List of Figures
Boehringer Ingelheim GmbH Snapshot
Boehringer Ingelheim GmbH Overview
Key Information
Key Facts
Boehringer Ingelheim GmbH - Research and Development Overview
Key Therapeutic Areas
Boehringer Ingelheim GmbH - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Boehringer Ingelheim GmbH - Pipeline Products Glance
Boehringer Ingelheim GmbH - Late Stage Pipeline Products
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products
Boehringer Ingelheim GmbH - Early Stage Pipeline Products
Boehringer Ingelheim GmbH - Drug Profiles
(empagliflozin + metformin hydrochloride)
(olodaterol + tiotropium bromide)
idarucizumab
tiotropium bromide
adalimumab biosimilar
afatinib dimaleate
bevacizumab biosimilar
empagliflozin
nintedanib
rituximab biosimilar
volasertib
BI-144807
BI-409306
BI-655066
FX-125L
VTP-34072
BI-836845
BI-836858
BI-1005273
BI-1015550
BI-1026706
BI-1060469
BI-113608
BI-1361849
BI-416970
BI-425809
BI-655064
BI-836826
BI-847325
BI-853520
BI-860585
PXS-4728A
Small Molecule for Cancer
BCA-909
BI-1147560
BI-186908
BI-207524 Follow-Up
BIBN-4096BS
CNX-012
CNX-012570
Monoclonal Antibodies for Autoimmune Disorders
Monoclonal Antibodies for Oncology and Immunology
Small Molecule 2 for Cancer
Small Molecule 3 for Cancer
Small Molecule for Respiratory Diseases
Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain
Small Molecule to Agonize Glucocorticoid Receptor for Inflammation
Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection
Small Molecules for Respiratory Disorders
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy
Synthetic Peptide for CardioMetabolic Disease
Synthetic Peptides to Agonize Glucagon and GLP-1 for Metabolic Disorders
Antibody for Cancer
BI-665915
Monoclonal Antibody for Undisclosed Indication
Small Molecule 2 to Agonize Glucocorticoid Receptor for Inflammation
Small Molecule for HIV
Small Molecule for HIV-1 Infection
Small Molecule to Agonize Glucocorticoid Receptor for Undisclosed Indication
Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders
Small Molecule to Inhibit Reverse Transcriptase for HIV-1
Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection
Small Molecules for Cancer
Small Molecules for Undisclosed Indication
Small Molecules to Inhibit K-Ras for Oncology
Small Molecules to Inhibit Kinases for Cancer
Boehringer Ingelheim GmbH - Pipeline Analysis
Boehringer Ingelheim GmbH - Pipeline Products by Target
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action
Boehringer Ingelheim GmbH - Recent Pipeline Updates
Boehringer Ingelheim GmbH - Dormant Projects
Boehringer Ingelheim GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Boehringer Ingelheim GmbH, Key Information
Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH - Pipeline by Indication, 2015
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2015
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
Boehringer Ingelheim GmbH - Pre-Registration, 2015
Boehringer Ingelheim GmbH - Phase III, 2015
Boehringer Ingelheim GmbH - Phase II, 2015
Boehringer Ingelheim GmbH - Phase I, 2015
Boehringer Ingelheim GmbH - Preclinical, 2015
Boehringer Ingelheim GmbH - Discovery, 2015
Boehringer Ingelheim GmbH - Pipeline by Target, 2015
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2015
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2015
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2015
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2015
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2015
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2015
Boehringer Ingelheim GmbH, Subsidiaries

List of Figures
Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2015
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2015
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Route of Administration, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Molecule Type, 2015
Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.